What Decheng Capital LLC reported holding on Form 13F for the quarter ended Sep 30, 2026.
CIK 2010850 · Filed Nov 13, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| 26M |
| ±0% |
| $145.3M |
| 21.2% |
ACRSAclaris Therapeutics, Inc. | 4M | ±0% | $21.3M | 3.1% |
AARDAardvark Therapeutics, Inc. | 3.9M | ±0% | $20.6M | 3% |
UPBUpstream Bio, Inc. | 2.7M | ±0% | $14.4M | 2.1% |
RCUSArcus Biosciences, Inc. | 425.1K | −8.5% | $11M | 1.6% |
EQEquillium, Inc. | 4.4M | ±0% | $7.2M | 1.1% |
Lyell Immunopharma, Inc.COM | 692.1K | ±0% | $6.8M | 1% |
ZNTLZentalis Pharmaceuticals, Inc. | 1.3M | ±0% | $3.7M | 0.5% |
BYSIBeyondSpring Inc. | 3.1M | −19.3% | $2.4M | 0.3% |
PYXSPyxis Oncology, Inc. | 326.8K | ±0% | $761.5K | 0.1% |